Market capitalization | €352.47m |
Enterprise Value | €284.00m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.66 |
P/S ratio (TTM) P/S ratio | 0.82 |
P/B ratio (TTM) P/B ratio | 3.32 |
Dividend yield | 1.40% |
Last dividend (FY23) | €0.17 |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
3 Analysts have issued a Ion Beam Applications forecast:
3 Analysts have issued a Ion Beam Applications forecast:
Dec '23 |
+/-
%
|
||
Turnover | 429 429 |
19%
19%
|
|
Gross income | 134 134 |
6%
6%
|
|
EBITDA | 18 18 |
18%
18%
|
EBIT (operating result) EBIT | 6.42 6.42 |
42%
42%
|
Net profit | -9.11 -9.11 |
250%
250%
|
Figures in millions EUR.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Ion Beam Applications SA engages in the design, manufacture, and marketing of cancer treatment and diagnosis equipment. It operates through the Proton Therapy and Other Accelerators; and Dosimetry segments. The Proton Therapy and Other Accelerators segment include development, fabrication, and services associated with medical and industrial particle accelerators and proton therapy systems. The Dosimetry segment comprises activities that offer a full range of solutions and services that maximize efficiency and minimize errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company was founded by Yves Jongen on March 28, 1986 and is headquartered in Louvain-la-Neuve, Belgium.
Head office | Belgium |
CEO | Olivier Legrain |
Employees | 1,986 |
Founded | 1986 |
Website | www.iba-worldwide.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.